Aethlon Medical (AEMD) investor relations material

Executive summary

• Advanced the Hemopurifier platform with progress in clinical research, including the Australian oncology study entering the third and final dosing cohort, and expanded intellectual property with new patents in the US and Europe.

• Expanded preclinical research into new disease areas, including rheumatoid arthritis and chronic kidney disease, supporting the device's platform potential.

• Maintained disciplined resource management and focus on clinical and research priorities.

Financial highlights

• Cash and cash equivalents stood at approximately $5 million as of March 31, 2026.

• Raised an additional $1.85 million in net proceeds after fiscal year-end through an at-the-market program.

• Operating expenses declined 21.9% year-over-year to $7.3 million, down from $9.3 million in the prior year.

• Net loss attributable to common stockholders was $7.2 million, a significant improvement from $13.4 million in the previous year.

• Other income was $142,000, compared to a $4 million other expense in the prior year, which included $4.7 million in non-cash financing charges.

Outlook and guidance

• Ongoing enrollment in the final cohort of the Australian oncology trial, with data generation expected upon completion.

• Continued evaluation of Hemopurifier applications in additional disease areas, including rheumatoid arthritis and chronic kidney disease.

• Focus on expanding the platform into large markets with significant unmet medical need.